TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 5, 2025 Registration No. 333-283249 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM F-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Baird Medical Investment Holdings Limited (Exact name of Registrant as specified in its charter) (I.R.S. Employer Identification Number) The Cayman Islands 3711 Not Applicable (State or other jurisdiction of incorporation or organization ...

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 8, 2025 Registration No. 333-283249 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT (I.R.S. Employer Identification Number) The Cayman Islands 3711 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Room 202, 2/F, Baide Building, Building 11, No.15 Rongtong Street, Yuexiu ...

Core Viewpoint - Karolinska Development AB has divested its remaining shares in OssDsign, resulting in a capital injection of approximately SEK 34.5 million, which strengthens the company's liquidity and allows for prioritization of other investments with greater value creation potential [1][2]. Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying breakthrough medical innovations in the Nordic region, investing in the creation and growth of companies that advance these innovations into commercial products [4][5]. - The company has access to world-class medical innovations from the Karolinska Institutet and other leading universities and research institutes in the Nordic region, aiming to build companies around leading scientists supported by experienced management teams [5][6]. Investment Strategy - The divestment from OssDsign reflects a strategic decision to realize profits and enhance the financial position of Karolinska Development, enabling the company to invest in other holdings with higher potential returns [2][3]. - Following the divestment, Karolinska Development has no direct ownership in OssDsign but retains indirect ownership through the KCIF Co-Investment Fund [3]. Portfolio and Management - Karolinska Development has a portfolio of eleven companies targeting innovative treatments for life-threatening or serious debilitating diseases, led by an entrepreneurial team of investment professionals with a proven track record [6].